1
|
Ming P, Wei Y, Zhu Y, Li K, Zhu W, Qiu J. Dual-stabilized selenium nanoparticles with chitosan and SS31 peptide: Resolving instability for enhancing ROS elimination, suppressing inflammation, and combating bacterial infections. Colloids Surf B Biointerfaces 2025; 253:114749. [PMID: 40318392 DOI: 10.1016/j.colsurfb.2025.114749] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/26/2025] [Revised: 04/13/2025] [Accepted: 04/27/2025] [Indexed: 05/07/2025]
Abstract
Selenium nanoparticles (SeNPs) hold significant promise for managing inflammatory microenvironments due to their anti-inflammatory, antioxidant, and tissue-regenerative properties. However, their poor stability limits practical applications. To address this, we developed a novel nanocomposite by co-stabilizing SeNPs with chitosan and the mitochondria-targeting peptide SS31 (CS/SS31-SeNPs) via a redox synthesis method. The optimized CS/SS31-SeNPs exhibited a uniform spherical structure (82 nm diameter, +48 mV zeta potential) and exceptional stability (no aggregation over 90 days), as confirmed by dynamic light scattering, TEM, EDX, XPS and TGA analyses. The nanocomposites demonstrated enhanced reactive oxygen species (ROS) scavenging efficiency in vitro and in vivo. In a copper sulfate-induced zebrafish inflammation model, CS/SS31-SeNPs pretreatment reduced neutrophil and macrophage recruitment by 38.07 % and 43.56 %, respectively, outperforming bare SeNPs. Furthermore, CS/SS31-SeNPs exhibited superior antibacterial activity against Staphylococcus aureus, achieving near-complete growth inhibition at 64 μM. Mechanistic studies revealed that the antibacterial action stems from targeting the conserved MraY enzyme in peptidoglycan synthesis. Molecular docking indicated stable binding (-15.6 kcal/mol) of CS/SS31-SeNPs to MraY's uracil pocket and adjacent sites-a mechanism distinct from conventional antibiotics, suggesting broad-spectrum potential. By synergistically integrating chitosan's antibacterial properties with SS31's mitochondrial targeting, CS/SS31-SeNPs overcome SeNPs instability while amplifying their therapeutic efficacy. This multifunctional platform offers a promising strategy for treating oral-craniofacial inflammatory and infectious diseases, with implications for antibiotic resistance mitigation.
Collapse
Affiliation(s)
- Panpan Ming
- Department of Oral Implantology, Affiliated Stomatological Hospital of Nanjing Medical University, Nanjing, PR China; Jiangsu Province Key Laboratory of Oral Diseases, Nanjing, PR China; Jiangsu Province Engineering Research Center of StomatologicalTranslational Medicine, Nanjing, PR China
| | - Yuwen Wei
- Department of Oral Implantology, Affiliated Stomatological Hospital of Nanjing Medical University, Nanjing, PR China; Jiangsu Province Key Laboratory of Oral Diseases, Nanjing, PR China; Jiangsu Province Engineering Research Center of StomatologicalTranslational Medicine, Nanjing, PR China
| | - Yawen Zhu
- Department of Oral Implantology, Affiliated Stomatological Hospital of Nanjing Medical University, Nanjing, PR China; Jiangsu Province Key Laboratory of Oral Diseases, Nanjing, PR China; Jiangsu Province Engineering Research Center of StomatologicalTranslational Medicine, Nanjing, PR China
| | - Kang Li
- Department of Oral Special Consultation, Affiliated Stomatological Hospital of Nanjing Medical University, Nanjing, PR China; Jiangsu Province Key Laboratory of Oral Diseases, Nanjing, PR China; Jiangsu Province Engineering Research Center of StomatologicalTranslational Medicine, Nanjing, PR China
| | - Wenqing Zhu
- Department of Oral Special Consultation, Affiliated Stomatological Hospital of Nanjing Medical University, Nanjing, PR China; Jiangsu Province Key Laboratory of Oral Diseases, Nanjing, PR China; Jiangsu Province Engineering Research Center of StomatologicalTranslational Medicine, Nanjing, PR China.
| | - Jing Qiu
- Department of Oral Implantology, Affiliated Stomatological Hospital of Nanjing Medical University, Nanjing, PR China; Jiangsu Province Key Laboratory of Oral Diseases, Nanjing, PR China; Jiangsu Province Engineering Research Center of StomatologicalTranslational Medicine, Nanjing, PR China.
| |
Collapse
|
2
|
Abd-El-Aziz A, Li Z, Zhang X, Elnagdy S, Mansour MS, ElSherif A, Ma N, Abd-El-Aziz AS. Advances in Coordination Chemistry of Schiff Base Complexes: A Journey from Nanoarchitectonic Design to Biomedical Applications. Top Curr Chem (Cham) 2025; 383:8. [PMID: 39900838 DOI: 10.1007/s41061-025-00489-w] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2024] [Accepted: 01/09/2025] [Indexed: 02/05/2025]
Abstract
Since the discovery of Schiff bases over one and a half centuries ago, there has been tremendous research activity in the design of various Schiff bases and examination of their diverse structures and versatile applications. This family of compounds has continued to captivate many research groups due to the simplicity of their synthesis through the condensation of amines with carbonyl compounds. While conventional synthesis has been the most widely used, green synthetic methodologies have been also explored for this reaction, including sonication, microwave-assisted, natural acid-catalyzed and mechanochemical syntheses as well as utilizing ionic liquid solvents or deep eutectic solvents. Schiff bases have been utilized as excellent ligands for coordination to transition metals and late transition metals (lanthanides and actinides). These Schiff base compounds can be mono-, di-, or polydentate ligands. The aim of this review is to examine the biological applications of Schiff base complexes over the past decade with particular focus on their antimicrobial, antiviral, anticancer, antidiabetic, and anti-inflammatory activity. Schiff base complexes have been found effective in combating bacterial and fungal infections with numerous examples in the literature. The review addressed this area by focusing on the very recent examples while using tables to summarize the vast breadth of research according to the metallic moieties. Viruses have continued to be a target of many researchers in light of their continuous mutations and impact on human health, and therefore some examples of Schiff base complexes with antiviral activity are described. Cancer continues to be among the leading causes of death worldwide. In this article, the use of Schiff base complexes for, and the mechanisms associated with, their anticancer activity are highlighted. The production of reactive oxygen species (ROS) or intercalation with DNA base pairs leading to cell cycle arrest were the main mechanisms described. While there have been some efforts made to use Schiff base complexes as antidiabetic or anti-inflammatory agents, there are limited examples when compared with antimicrobial and anticancer studies. The conclusion of this review highlights the emerging areas of research and future perspectives with an emphasis on the potential uses of Schiff bases in the treatment of infectious and noninfectious diseases.
Collapse
Affiliation(s)
- Ahmad Abd-El-Aziz
- College of Materials Science and Chemical Engineering, Harbin Engineering University, Harbin, 150001, China
- Qingdao Innovation and Development Center, Harbin Engineering University, Qingdao, 266400, China
| | - Zexuan Li
- College of Materials Science and Chemical Engineering, Harbin Engineering University, Harbin, 150001, China
- Qingdao Innovation and Development Center, Harbin Engineering University, Qingdao, 266400, China
| | - Xinyue Zhang
- College of Materials Science and Chemical Engineering, Harbin Engineering University, Harbin, 150001, China
- Qingdao Innovation and Development Center, Harbin Engineering University, Qingdao, 266400, China
| | - Sherif Elnagdy
- Department of Botany and Microbiology, Faculty of Science, Cairo University, Giza, Egypt
| | - Mohamed S Mansour
- Department of Chemistry, Faculty of Science, Cairo University, Giza, Egypt
| | - Ahmed ElSherif
- Department of Chemistry, Faculty of Science, Cairo University, Giza, Egypt
| | - Ning Ma
- College of Materials Science and Chemical Engineering, Harbin Engineering University, Harbin, 150001, China
- Qingdao Innovation and Development Center, Harbin Engineering University, Qingdao, 266400, China
| | - Alaa S Abd-El-Aziz
- College of Materials Science and Chemical Engineering, Harbin Engineering University, Harbin, 150001, China.
- Qingdao Innovation and Development Center, Harbin Engineering University, Qingdao, 266400, China.
| |
Collapse
|
3
|
Berida T, Huang TY, Weck SC, Lutz M, McKee SR, Kagerah N, Manning D, Jahan ME, Mishra SK, Doerksen RJ, Stallings CL, Ducho C, Roy S. 1,2,4-Triazole-based first-in-class non-nucleoside inhibitors of bacterial enzyme MraY. BIORXIV : THE PREPRINT SERVER FOR BIOLOGY 2025:2025.01.30.635793. [PMID: 39975250 PMCID: PMC11838528 DOI: 10.1101/2025.01.30.635793] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/21/2025]
Abstract
MraY, a bacterial enzyme crucial for the synthesis of peptidoglycans, represents a promising yet underexplored target for the development of effective antibacterial agents. Nature has provided several classes of nucleoside inhibitors of MraY and scientists have modified these structures further to obtain natural product-like inhibitors of MraY. The natural products and their synthetic analogs suffer from non-optimal in vivo efficacy, and the synthetic complexity of the structures renders the synthesis and structure-activity relationship (SAR) studies of these molecules particularly challenging. In this study, we present our findings on the discovery of first-in-class 1,2,4-triazole-based MraY inhibitors that are not nucleoside-derived. A series of 1,2,4-triazole analogous were identified by a structure-activity-relationship (SAR) study using a structure-based drug design strategy. Compound 1 , with an IC 50 of 171 µM against MraY from Staphylococcus aureus (MraY SA ), was optimized to compound 12a , exhibiting an IC 50 of 25 µM. Molecular docking studies against MraY SA provided insights into these compounds' binding interactions and activity. Furthermore, screening against the ESKAPE bacterial panel was also conducted, through which we discovered compounds demonstrating broad-spectrum antibacterial activity against E. faecium , methicillin-resistant S. aureus (MRSA), vancomycin-resistant Enterococci (VRE) strains and Mycobacterium tuberculosis . The novel, first-in-class non-nucleoside inhibitors of MraY highlighted in this work provide a strong proof-of-concept of how to leverage structural information of the protein to develop future antibacterial agents targeting MraY. Abstract Figure
Collapse
|
4
|
Paddy I, Dassama LMK. Identifying Opportunity Targets in Gram-Negative Pathogens for Infectious Disease Mitigation. ACS CENTRAL SCIENCE 2025; 11:25-35. [PMID: 39866699 PMCID: PMC11758222 DOI: 10.1021/acscentsci.4c01437] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 09/02/2024] [Revised: 11/15/2024] [Accepted: 12/20/2024] [Indexed: 01/28/2025]
Abstract
Antimicrobial drug resistance (AMR) is a pressing global human health challenge. Humans face one of their grandest challenges as climate change expands the habitat of vectors that bear human pathogens, incidences of nosocomial infections rise, and new antibiotics discovery lags. AMR is a multifaceted problem that requires a multidisciplinary and an "all-hands-on-deck" approach. As chemical microbiologists, we are well positioned to understand the complexities of AMR while seeing opportunities for tackling the challenge. In this Outlook, we focus on vulnerabilities of human pathogens and posit that they represent "opportunity targets" for which few modulatory ligands exist. We center our attention on proteins in Gram-negative organisms, which are recalcitrant to many antibiotics because of their external membrane barrier. Our hope is to highlight such targets and explore their potential as "druggable" proteins for infectious disease mitigation. We posit that success in this endeavor will introduce new classes of antibiotics that might alleviate some of the current pressing AMR concerns.
Collapse
Affiliation(s)
- Isaac
A. Paddy
- Department
of Chemical and Systems Biology, Stanford
School of Medicine, Stanford, California 94305-6104, United States
- Sarafan
ChEM-H Institute, Stanford University, Stanford, California 94305-6104, United
States
| | - Laura M. K. Dassama
- Sarafan
ChEM-H Institute, Stanford University, Stanford, California 94305-6104, United
States
- Department
of Chemistry, Stanford University, Stanford, California 94305-6104, United
States
- Department
Microbiology & Immunology, Stanford
School of Medicine, Stanford, California 94305-6104, United States
| |
Collapse
|
5
|
Yamamoto K, Sato T, Hao A, Asao K, Kaguchi R, Kusaka S, Ruddarraju RR, Kazamori D, Seo K, Takahashi S, Horiuchi M, Yokota SI, Lee SY, Ichikawa S. Development of a natural product optimization strategy for inhibitors against MraY, a promising antibacterial target. Nat Commun 2024; 15:5085. [PMID: 38877016 PMCID: PMC11178787 DOI: 10.1038/s41467-024-49484-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/30/2023] [Accepted: 06/06/2024] [Indexed: 06/16/2024] Open
Abstract
MraY (phospho-N-acetylmuramoyl-pentapeptide-transferase) inhibitory natural products are attractive molecules as candidates for a new class of antibacterial agents to combat antimicrobial-resistant bacteria. Structural optimization of these natural products is required to improve their drug-like properties for therapeutic use. However, chemical modifications of these natural products are painstaking tasks due to complex synthetic processes, which is a bottleneck in advancing natural products to the clinic. Here, we develop a strategy for a comprehensive in situ evaluation of the build-up library, which enables us to streamline the preparation of the analogue library and directly assess its biological activities. We apply this approach to a series of MraY inhibitory natural products. Through construction and evaluation of the 686-compound library, we identify promising analogues that exhibit potent and broad-spectrum antibacterial activity against highly drug-resistant strains in vitro as well as in vivo in an acute thigh infection model. Structures of the MraY-analogue complexes reveal distinct interaction patterns, suggesting that these analogues represent MraY inhibitors with unique binding modes. We further demonstrate the generality of our strategy by applying it to tubulin-binding natural products to modulate their tubulin polymerization activities.
Collapse
Grants
- 22K20704 MEXT | Japan Society for the Promotion of Science (JSPS)
- 21H03622 MEXT | Japan Society for the Promotion of Science (JSPS)
- JP19K16648 MEXT | Japan Society for the Promotion of Science (JSPS)
- 19H03345 MEXT | Japan Society for the Promotion of Science (JSPS)
- 18H04599 MEXT | Japan Society for the Promotion of Science (JSPS)
- 20H04757 MEXT | Japan Society for the Promotion of Science (JSPS)
- JP19ak0101118h0001 Japan Agency for Medical Research and Development (AMED)
- 21ak0101118h9903 Japan Agency for Medical Research and Development (AMED)
- JP18am0101093j0002 Japan Agency for Medical Research and Development (AMED)
- JP22ama121039 Japan Agency for Medical Research and Development (AMED)
- JP23gm1610012 Japan Agency for Medical Research and Development (AMED)
- JP23gm1610013 Japan Agency for Medical Research and Development (AMED)
- JST START Program: ST211004JO Japan Initiative for Global Research Network on Infectious Diseases (J-GRID) from the Ministry of Education, Culture, Sport, Science, and Technology in Japan, MEXT for the Joint Research Program of the Research Center for Zoonosis Control, Hokkaido University
- the Duke Science Technology Scholar Fund
- Takeda Foundation, The Tokyo Biomedical Research Foundation and was partly supported by Hokkaido University, Global Facility Center (GFC), Pharma Science Open Unit (PSOU), funded by MEXT under "Support Program for Implementation of New Equipment Sharing System"
Collapse
Affiliation(s)
- Kazuki Yamamoto
- Faculty of Pharmaceutical Sciences, Hokkaido University, Kita-12, Nishi-6, Kita-ku, Sapporo, 060-0812, Japan.
- Center for Research and Education on Drug Discovery, Faculty of Pharmaceutical Sciences, Hokkaido University, Kita-12, Nishi-6, Kita-ku, Sapporo, 060-0812, Japan.
| | - Toyotaka Sato
- Laboratory of Veterinary Hygiene, School/Faculty of Veterinary Medicine, Hokkaido University, Kita-18, Nishi-9, Kita-ku, Sapporo, 060-0818, Japan
- Graduate School of Infectious Diseases, Hokkaido University, Kita-18, Nishi-9, Kita-ku, Sapporo, 060-0818, Japan
- One Health Research Center, Hokkaido University, Kita-18, Nishi-9, Kita-ku, Sapporo, 060-0818, Japan
| | - Aili Hao
- Department of Biochemistry, Duke University School of Medicine, Durham, NC, 27710, USA
| | - Kenta Asao
- Faculty of Pharmaceutical Sciences, Hokkaido University, Kita-12, Nishi-6, Kita-ku, Sapporo, 060-0812, Japan
| | - Rintaro Kaguchi
- Faculty of Pharmaceutical Sciences, Hokkaido University, Kita-12, Nishi-6, Kita-ku, Sapporo, 060-0812, Japan
| | - Shintaro Kusaka
- Faculty of Pharmaceutical Sciences, Hokkaido University, Kita-12, Nishi-6, Kita-ku, Sapporo, 060-0812, Japan
| | | | - Daichi Kazamori
- Drug Discovery Laboratory, Wakunaga Pharmaceutical Co., Ltd., 1624, Shimokotachi, Koda-cho, Akitakata-shi, Hiroshima, 739-1195, Japan
| | - Kiki Seo
- Drug Discovery Laboratory, Wakunaga Pharmaceutical Co., Ltd., 1624, Shimokotachi, Koda-cho, Akitakata-shi, Hiroshima, 739-1195, Japan
| | - Satoshi Takahashi
- Division of Laboratory Medicine, Sapporo Medical University Hospital, Minami-1, Nishi-16, Chuo-ku, Sapporo, 060-8543, Japan
- Department of Infection Control and Laboratory Medicine, Sapporo Medical University School of Medicine, Minami-1, Nishi-16, Chuo-ku, Sapporo, 060-8543, Japan
| | - Motohiro Horiuchi
- Laboratory of Veterinary Hygiene, School/Faculty of Veterinary Medicine, Hokkaido University, Kita-18, Nishi-9, Kita-ku, Sapporo, 060-0818, Japan
- Graduate School of Infectious Diseases, Hokkaido University, Kita-18, Nishi-9, Kita-ku, Sapporo, 060-0818, Japan
- One Health Research Center, Hokkaido University, Kita-18, Nishi-9, Kita-ku, Sapporo, 060-0818, Japan
| | - Shin-Ichi Yokota
- Department of Microbiology, Sapporo Medical University School of Medicine, Minami-1, Nishi-17, Chuo-ku, Sapporo, 060-8556, Japan
| | - Seok-Yong Lee
- Department of Biochemistry, Duke University School of Medicine, Durham, NC, 27710, USA
| | - Satoshi Ichikawa
- Faculty of Pharmaceutical Sciences, Hokkaido University, Kita-12, Nishi-6, Kita-ku, Sapporo, 060-0812, Japan.
- Center for Research and Education on Drug Discovery, Faculty of Pharmaceutical Sciences, Hokkaido University, Kita-12, Nishi-6, Kita-ku, Sapporo, 060-0812, Japan.
- Global Institution for Collaborative Research and Education (GI-CoRE), Hokkaido University, Kita-12, Nishi-6, Kita-ku, Sapporo 060-0812, Sapporo, Japan.
| |
Collapse
|
6
|
Theuretzbacher U, Blasco B, Duffey M, Piddock LJV. Unrealized targets in the discovery of antibiotics for Gram-negative bacterial infections. Nat Rev Drug Discov 2023; 22:957-975. [PMID: 37833553 DOI: 10.1038/s41573-023-00791-6] [Citation(s) in RCA: 31] [Impact Index Per Article: 15.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 08/15/2023] [Indexed: 10/15/2023]
Abstract
Advances in areas that include genomics, systems biology, protein structure determination and artificial intelligence provide new opportunities for target-based antibacterial drug discovery. The selection of a 'good' new target for direct-acting antibacterial compounds is the first decision, for which multiple criteria must be explored, integrated and re-evaluated as drug discovery programmes progress. Criteria include essentiality of the target for bacterial survival, its conservation across different strains of the same species, bacterial species and growth conditions (which determines the spectrum of activity of a potential antibiotic) and the level of homology with human genes (which influences the potential for selective inhibition). Additionally, a bacterial target should have the potential to bind to drug-like molecules, and its subcellular location will govern the need for inhibitors to penetrate one or two bacterial membranes, which is a key challenge in targeting Gram-negative bacteria. The risk of the emergence of target-based drug resistance for drugs with single targets also requires consideration. This Review describes promising but as-yet-unrealized targets for antibacterial drugs against Gram-negative bacteria and examples of cognate inhibitors, and highlights lessons learned from past drug discovery programmes.
Collapse
Affiliation(s)
| | - Benjamin Blasco
- Global Antibiotic Research and Development Partnership (GARDP), Geneva, Switzerland
| | - Maëlle Duffey
- Global Antibiotic Research and Development Partnership (GARDP), Geneva, Switzerland
| | - Laura J V Piddock
- Global Antibiotic Research and Development Partnership (GARDP), Geneva, Switzerland.
| |
Collapse
|
7
|
Chen L, Kumar S, Wu H. A review of current antibiotic resistance and promising antibiotics with novel modes of action to combat antibiotic resistance. Arch Microbiol 2023; 205:356. [PMID: 37863957 DOI: 10.1007/s00203-023-03699-2] [Citation(s) in RCA: 17] [Impact Index Per Article: 8.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/25/2023] [Revised: 09/25/2023] [Accepted: 10/03/2023] [Indexed: 10/22/2023]
Abstract
The emergence and transmission of antibiotic resistance is a global public health crisis with significant burden on healthcare systems, resulting in high mortality and economic costs. In 2019, almost five million deaths were associated with drug-resistant infections, and if left unchecked, the global economy could lose $100 trillion by 2050. To effectively combat this crisis, it is essential for all countries to understand the current situation of antibiotic resistance. In this review, we examine the current driving factors leading to the crisis, impact of critical superbugs in three regions, and identify novel mechanisms of antibiotic resistance. It is crucial to monitor the phenotypic characteristics of drug-resistant pathogens and describe the mechanisms involved in preventing the emergence of cross-resistance to novel antimicrobials. Additionally, maintaining an active pipeline of new antibiotics is essential for fighting against diverse antibiotic-resistant pathogens. Developing antibacterial agents with novel mechanisms of action is a promising way to combat increasing antibiotic-resistant pathogens.
Collapse
Affiliation(s)
- Lei Chen
- Jiangsu Vocational College of Medicine, Yancheng, China
- School of Graduate Studies, Management and Science University, Shah Alam, Malaysia
| | - Suresh Kumar
- Faculty of Health and Life Sciences, Management and Science University, Shah Alam, Malaysia.
| | - Hongyan Wu
- Jiangsu Vocational College of Medicine, Yancheng, China
| |
Collapse
|
8
|
Manning D, Huang TY, Berida T, Roy S. The challenges and opportunities of developing small molecule inhibitors of MraY. ANNUAL REPORTS IN MEDICINAL CHEMISTRY 2023; 60:1-27. [PMID: 39015353 PMCID: PMC11250723 DOI: 10.1016/bs.armc.2023.09.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 07/18/2024]
Affiliation(s)
- Destinee Manning
- Department of BioMolecular Sciences, University of Mississippi, University, MS, United States
| | - Tzu-Yu Huang
- Department of BioMolecular Sciences, University of Mississippi, University, MS, United States
| | - Tomayo Berida
- Department of BioMolecular Sciences, University of Mississippi, University, MS, United States
| | - Sudeshna Roy
- Department of BioMolecular Sciences, University of Mississippi, University, MS, United States
| |
Collapse
|
9
|
Yoon D, Moon JH, Cho A, Boo H, Cha JS, Lee Y, Yoo J. Structure-Based Insight on the Mechanism of N-Glycosylation Inhibition by Tunicamycin. Mol Cells 2023; 46:337-344. [PMID: 37190766 PMCID: PMC10258461 DOI: 10.14348/molcells.2023.0001] [Citation(s) in RCA: 15] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/01/2023] [Revised: 02/14/2023] [Accepted: 02/20/2023] [Indexed: 05/17/2023] Open
Abstract
N-glycosylation, a common post-translational modification, is widely acknowledged to have a significant effect on protein stability and folding. N-glycosylation is a complex process that occurs in the endoplasmic reticulum (ER) and requires the participation of multiple enzymes. GlcNAc-1-P-transferase (GPT) is essential for initiating N-glycosylation in the ER. Tunicamycin is a natural product that inhibits N-glycosylation and produces ER stress, and thus it is utilized in research. The molecular mechanism by which GPT triggers N-glycosylation is discussed in this review based on the GPT structure. Based on the structure of the GPT-tunicamycin complex, we also discuss how tunicamycin reduces GPT activity, which prevents N-glycosylation. This review will be highly useful for understanding the role of GPT in the N-glycosylation of proteins, as well as presents a potential for considering tunicamycin as an antibiotic treatment.
Collapse
Affiliation(s)
- Danbi Yoon
- College of Pharmacy, Chung-Ang University, Seoul 06974, Korea
| | - Ju Heun Moon
- College of Pharmacy, Chung-Ang University, Seoul 06974, Korea
| | - Anna Cho
- College of Pharmacy, Chung-Ang University, Seoul 06974, Korea
| | - Hyejoon Boo
- College of Pharmacy, Chung-Ang University, Seoul 06974, Korea
| | - Jeong Seok Cha
- College of Pharmacy, Chung-Ang University, Seoul 06974, Korea
| | - Yoonji Lee
- College of Pharmacy, Chung-Ang University, Seoul 06974, Korea
| | - Jiho Yoo
- College of Pharmacy, Chung-Ang University, Seoul 06974, Korea
| |
Collapse
|
10
|
Bremner JB. An Update Review of Approaches to Multiple Action-Based Antibacterials. Antibiotics (Basel) 2023; 12:antibiotics12050865. [PMID: 37237768 DOI: 10.3390/antibiotics12050865] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/14/2023] [Revised: 05/01/2023] [Accepted: 05/04/2023] [Indexed: 05/28/2023] Open
Abstract
Many approaches are being pursued to address the major global health challenge posed by the increasing resistance of pathogenic bacteria to antibacterial agents. One of the promising approaches being investigated includes the design and development of multiple action-based small-molecule antibacterials. Aspects of this broad area have been reviewed previously, and recent developments are addressed in this update review covering the literature mainly over the past three years. Considerations encompassing drug combinations, single-molecule hybrids and prodrugs are summarised in regard to the intentional design and development of multiple-action agents with a focus on potential triple or greater activities in bacteria. The hope for such single agents or combinations of single agents is that resistance development will be significantly hindered, and they may be useful in tackling bacterial disease caused by both resistant and non-resistant bacteria.
Collapse
Affiliation(s)
- John B Bremner
- School of Chemistry and Molecular Bioscience, University of Wollongong, Wollongong, NSW 2522, Australia
| |
Collapse
|
11
|
Hornyak T. How Japanese science is trying to reassert its research strength. Nature 2023; 615:S48-S51. [PMID: 36890380 DOI: 10.1038/d41586-023-00657-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/10/2023]
|
12
|
Gago F. Computational Approaches to Enzyme Inhibition by Marine Natural Products in the Search for New Drugs. Mar Drugs 2023; 21:100. [PMID: 36827141 PMCID: PMC9961086 DOI: 10.3390/md21020100] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2022] [Revised: 01/26/2023] [Accepted: 01/28/2023] [Indexed: 02/03/2023] Open
Abstract
The exploration of biologically relevant chemical space for the discovery of small bioactive molecules present in marine organisms has led not only to important advances in certain therapeutic areas, but also to a better understanding of many life processes. The still largely untapped reservoir of countless metabolites that play biological roles in marine invertebrates and microorganisms opens new avenues and poses new challenges for research. Computational technologies provide the means to (i) organize chemical and biological information in easily searchable and hyperlinked databases and knowledgebases; (ii) carry out cheminformatic analyses on natural products; (iii) mine microbial genomes for known and cryptic biosynthetic pathways; (iv) explore global networks that connect active compounds to their targets (often including enzymes); (v) solve structures of ligands, targets, and their respective complexes using X-ray crystallography and NMR techniques, thus enabling virtual screening and structure-based drug design; and (vi) build molecular models to simulate ligand binding and understand mechanisms of action in atomic detail. Marine natural products are viewed today not only as potential drugs, but also as an invaluable source of chemical inspiration for the development of novel chemotypes to be used in chemical biology and medicinal chemistry research.
Collapse
Affiliation(s)
- Federico Gago
- Department of Biomedical Sciences & IQM-CSIC Associate Unit, School of Medicine and Health Sciences, University of Alcalá, E-28805 Madrid, Alcalá de Henares, Spain
| |
Collapse
|
13
|
Xie M, Gao M, Yun Y, Malmsten M, Rotello VM, Zboril R, Akhavan O, Kraskouski A, Amalraj J, Cai X, Lu J, Zheng H, Li R. Antibacterial Nanomaterials: Mechanisms, Impacts on Antimicrobial Resistance and Design Principles. Angew Chem Int Ed Engl 2023; 62:e202217345. [PMID: 36718001 DOI: 10.1002/anie.202217345] [Citation(s) in RCA: 121] [Impact Index Per Article: 60.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/24/2022] [Revised: 01/27/2023] [Accepted: 01/30/2023] [Indexed: 02/01/2023]
Abstract
Antimicrobial resistance (AMR) is one of the biggest threats to the environment and health. AMR rapidly invalidates conventional antibiotics, and antimicrobial nanomaterials have been increasingly explored as alternatives. Interestingly, several antimicrobial nanomaterials show AMR-independent antimicrobial effects without detectable new resistance and have therefore been suggested to prevent AMR evolution. In contrast, some are found to trigger the evolution of AMR. Given these seemingly conflicting findings, a timely discussion of the two faces of antimicrobial nanomaterials is urgently needed. This review systematically compares the killing mechanisms and structure-activity relationships of antibiotics and antimicrobial nanomaterials. We then focus on nano-microbe interactions to elucidate the impacts of molecular initiating events on AMR evolution. Finally, we provide an outlook on future antimicrobial nanomaterials and propose design principles for the prevention of AMR evolution.
Collapse
Affiliation(s)
- Maomao Xie
- State Key Laboratory of Radiation Medicine and Protection, School for Radiological and Interdisciplinary Sciences (RAD-X), Collaborative Innovation Center of Radiological Medicine of Jiangsu Higher Education Institutions, Suzhou Medical College, Soochow University, Suzhou, 215123, Jiangsu, China
| | - Meng Gao
- State Key Laboratory of Radiation Medicine and Protection, School for Radiological and Interdisciplinary Sciences (RAD-X), Collaborative Innovation Center of Radiological Medicine of Jiangsu Higher Education Institutions, Suzhou Medical College, Soochow University, Suzhou, 215123, Jiangsu, China
| | - Yang Yun
- College of Environmental & Resource Sciences, Shanxi University, Taiyuan, 030006, Shanxi, China
| | - Martin Malmsten
- Department of Pharmacy, University of Copenhagen, 2100, Copenhagen, Denmark.,Department of Physical Chemistry 1, University of Lund, 22100, Lund, Sweden
| | - Vincent M Rotello
- Department of Chemistry, University of Massachusetts Amherst, 710 N. Pleasant St., Amherst, USA
| | - Radek Zboril
- Regional Centre of Advanced Technologies and Materials, Czech Advanced Technology and Research Institute (CATRIN), Palacký University Olomouc, Šlechtitelů 241/27, Olomouc, 783 71, Czech Republic.,Nanotechnology Centre, Centre of Energy and Environmental Technologies, VŠB-Technical University of Ostrava, 17. listopadu 2172/15, Ostrava-Poruba, 708 00, Czech Republic
| | - Omid Akhavan
- Condensed Matter National Laboratory, P.O. Box 1956838861, Tehran, Iran
| | - Aliaksandr Kraskouski
- Department of Physicochemistry of Thin Film Materials, Institute of Chemistry of New Materials of NAS of Belarus, 36 F. Skaryna Str., 220084, Minsk, Belarus
| | - John Amalraj
- Laboratory of Materials Science, Instituto de Química de Recursos Naturales, Universidad de Talca, P.O. Box 747, Talca, Chile
| | - Xiaoming Cai
- School of Public Health, Suzhou Medical College, Soochow University, Suzhou, Jiangsu, 215123, China
| | - Jianmei Lu
- College of Chemistry, Chemical Engineering and Materials Science, National Center for International Research on Intelligent Nano-Materials and Detection Technology in Environmental Protection, Soochow University, Suzhou, 215123, China
| | - Huizhen Zheng
- State Key Laboratory of Radiation Medicine and Protection, School for Radiological and Interdisciplinary Sciences (RAD-X), Collaborative Innovation Center of Radiological Medicine of Jiangsu Higher Education Institutions, Suzhou Medical College, Soochow University, Suzhou, 215123, Jiangsu, China
| | - Ruibin Li
- State Key Laboratory of Radiation Medicine and Protection, School for Radiological and Interdisciplinary Sciences (RAD-X), Collaborative Innovation Center of Radiological Medicine of Jiangsu Higher Education Institutions, Suzhou Medical College, Soochow University, Suzhou, 215123, Jiangsu, China
| |
Collapse
|